MUC16 and neoplasm: Clinical activity, determined by RECIST v.1.1 and/or tumor marker (eg, prostate-specific antigen, cancer antigen-125 [CA-125]) responses was observed in all 3 dose groups with overall response rates of 8.7% (120 3/4), 9.2% (160 3/4), and 19.2% (160 3/4, 2/1w; Figures 2, A and B; Table 4; Supplementary Table 3, available online).